EGF Receptor / EGFR Antibody

Biorbyt

EGF Receptor / EGFR Antibody

10

Optimal dilution of the EGF Receptor antibody should be determined by the researcher.

Western Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin

Immunohistochemistry (FFPE): 0.1-0.2ug/ml for 30 min at RT,Western blot: 1-2ug/ml IHC-P, WB

Research Use Only

Monoclonal

GFR/1708

Unconjugated

EGFR

epidermal growth factor receptor

ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS, PIG61, mENA, epidermal growth factor receptor, EGFR vIII, avian erythroblastic leukemia viral (v-erb-b) oncogene homolog, cell growth inhibiting protein 40, cell proliferation-inducing protein 61, epidermal growth factor receptor tyrosine kinase domain, erb-b2 receptor tyrosine kinase 1, proto-oncogene c-ErbB-1, receptor tyrosine-protein kinase erbB-1

Mouse

IgG1

Epidermal growth factor receptor

Epidermal growth factor receptor (EGFR) exists on the cell surface and is activated by binding of its specific ligands, including epidermal growth factor and transforming growth factor a. Upon activation by its growth factor ligands, EGFR undergoes a transition from an inactive monomeric form to an active homodimer. In addition to forming homodimers after ligand binding, EGFR may pair with another member of the ErbB receptor family, such as ErbB2/Her2/neu, to create an activated heterodimer. EGFR dimerization stimulates its intrinsic intracellular protein-tyrosine kinase activity. As a result, autophosphorylation of several tyrosine (Y) residues in the C-terminal domain of EGFR occurs. This autophosphorylation elicits downstream activation and signaling by several other proteins that associate with the phosphorylated tyrosines through their own phosphotyrosine-binding SH2 domains. These downstream signaling proteins initiate several signal transduction cascades, principally the MAPK, Akt and JNK pathways, leading to DNA synthesis and cell proliferation. [Wiki]

Human

-20°C,2°C to 8°C

12352203